Clinical Trial Update: Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing the sequence of first-line docetaxel/prednisone followed by cabazitaxel/prednisone versus the reverse order in men with metastatic cas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Cabazitaxel (cabazitaxel)
• DOCETAXEL (DOCETAXEL)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2017-11-20